Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data

Fig. 4

Adjusted Kaplan–Meier progression-free survival estimates. a Overall NAVIGATOR population vs Study 1002. b NAVIGATOR 300/400 mg subgroup vs Study 1002. c Adjusted PFS landmark analyses for NAVIGATOR population and Study 1002. d Adjusted PFS analyses for NAVIGATOR 300/400 mg subgroup and Study 1002

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us